Donor lymphocyte infusion (DLI) can produce durable remissions in patients with chronic myelogenous leukemia (CML) who have a relapse after an allogeneic ...
Missing: decides | Show results with:decides
Donor lymphocyte infusions (DLI) are an effective treatment for relapsed chronic myeloid leukemia (CML) after allogeneic stem cell transplantation (alloSCT).
Jun 30, 2014 · There was a tendency for a better outcome regarding the time from molecular relapse to first DLI for patients receiving DLI after six months ...
These results indicate that UDLI may have efficacy in relapsed patients with CML, low tumor burden, or occurrence of GVHD after UDLI.
Missing: decides | Show results with:decides
Nineteen of 39 patients (48.7%) with relapsed disease achieved remission after DLI. In this cohort, attaining T-FDC impacted favorably in disease control (76.7% ...
Jan 29, 2022 · We carried out a retrospective study with 100 adult patients to identify patient and donor factors that can predict achievement of FDC and disease remission.
DLI has been found to be most effective in chronic myelogenous leukemia (CML), inducing a molecular complete remission (CR) in up to 80% of patients who relapse ...
Missing: decides | Show results with:decides
Whatever the indication for DLI, mortality related to post-DLI infusion is 5%–20%, and more than one-third of patients will develop acute and/or chronic graft ...
Aug 27, 2019 · We present our study on the use of donor lymphocyte infusion (DLI) in relapsing patients after alloHSCT with a novel approach using the intra-bone (IB) route.
Feb 1, 2002 · ROME-Best outcomes from donor lymphocyte infusion in chronic myelogenous leukemia (CML) occur when the first dose does not exceed 0.2 × 108 ...
Missing: decides | Show results with:decides